PMID- 38417609
OWN - NLM
STAT- MEDLINE
DCOM- 20240322
LR  - 20240322
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 969
DP  - 2024 Apr 15
TI  - Cellular and molecular mechanisms of oroxylin A in cancer therapy: Recent 
      advances.
PG  - 176452
LID - S0014-2999(24)00140-7 [pii]
LID - 10.1016/j.ejphar.2024.176452 [doi]
AB  - Seeking an effective and safe scheme is the common goal of clinical treatment of 
      tumor patients. In recent years, traditional Chinese medicine has attracted more 
      and more attention in order to discover new drugs with good anti-tumor effects. 
      Oroxylin A (OA) is a compound found in natural Oroxylum indicum and Scutellaria 
      baicalensis Georgi plants and has been used in the treatment of various cancers. 
      Studies have shown that OA has a wide range of powerful biological activities and 
      plays an important role in neuroprotection, anti-inflammation, anti-virus, 
      anti-allergy, anti-tumor and so on. OA shows high efficacy in tumor treatment. 
      Therefore, it has attracted great attention of researchers all over the world. 
      This review aims to discuss the anti-tumor effects of OA from the aspects of cell 
      cycle arrest, induction of cell proliferation and apoptosis, induction of 
      autophagy, anti-inflammation, inhibition of glycolysis, angiogenesis, invasion, 
      metastasis and reversal of drug resistance. In addition, the safety and toxicity 
      of the compound were also discussed. As a next step, to clarify the benefits and 
      adverse effects of Oroxylin A in cancer patients further experiments, especially 
      clinical trials, are needed.
CI  - Copyright (c) 2024 Elsevier B.V. All rights reserved.
FAU - Wang, Peng-Xin
AU  - Wang PX
AD  - Departments of Thoracic Surgery, Central Hospital Affiliated to Shandong First 
      Medical University, Jinan 250013, Shandong, China; Medical College, Jining 
      Medical University, Jining 272067, Shandong, China.
FAU - Mu, Xiao-Nan
AU  - Mu XN
AD  - Health Care (& Geriatrics) Ward 1, Central Hospital Affiliated to Shandong First 
      Medical University, Jinan, 250013, Shandong, China.
FAU - Huang, Shu-Hong
AU  - Huang SH
AD  - School of Clinical and Basic Medical Sciences, Shandong Provincial Hospital 
      Affiliated to Shandong First Medical University, Jinan, 250062, Shandong, China.
FAU - Hu, Kang
AU  - Hu K
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Soochow 
      University, Suzhou Medical College of Soochow University, Suzhou, 215000, 
      Jiangsu, China. Electronic address: 20237832036@stu.suda.edu.cn.
FAU - Sun, Zhi-Gang
AU  - Sun ZG
AD  - Departments of Thoracic Surgery, Central Hospital Affiliated to Shandong First 
      Medical University, Jinan 250013, Shandong, China. Electronic address: 
      jnszxyyyjs@jn.shandong.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240228
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 53K24Z586G (5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one)
RN  - 0 (Flavonoids)
SB  - IM
MH  - Humans
MH  - *Flavonoids/pharmacology/therapeutic use
MH  - Apoptosis
MH  - Cell Proliferation
MH  - Autophagy
MH  - *Neoplasms/drug therapy
OTO - NOTNLM
OT  - Apoptosis
OT  - Cancer
OT  - Metastasis
OT  - Molecular mechanisms
OT  - Oroxylin A
OT  - Traditional Chinese medicine
COIS- Declaration of competing interest The authors declare no conflicts of interest.
EDAT- 2024/02/29 00:42
MHDA- 2024/03/22 06:44
CRDT- 2024/02/28 19:16
PHST- 2023/10/31 00:00 [received]
PHST- 2024/02/04 00:00 [revised]
PHST- 2024/02/20 00:00 [accepted]
PHST- 2024/03/22 06:44 [medline]
PHST- 2024/02/29 00:42 [pubmed]
PHST- 2024/02/28 19:16 [entrez]
AID - S0014-2999(24)00140-7 [pii]
AID - 10.1016/j.ejphar.2024.176452 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2024 Apr 15;969:176452. doi: 10.1016/j.ejphar.2024.176452. Epub 
      2024 Feb 28.